FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Creative Peptides Shortened Their Supply Turnaround Time April 13, 2017 At Last: Eli Lilly Publishes Data for Catastrophic Alzheimer's Trial January 24, 2018 FDA Green Lights Pfizer Drug for Rare, Fast-Killing Type of Leukemia August 17, 2017
